Heather D Turner
CIK 1403571 · Chief Executive Officer · last filed 2026-05-05
Heather D Turner is a Chief Executive Officer who has filed 36 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for TERN, was dated May 5, 2026. Across all open-market trades the lifetime net is −$2.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $23.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OREX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | — | $52.95 | — | $0 | 4 | 2026-05-05 |
| AVLN | Director | — | $31.04 | — | $0 | 1 | 2026-05-01 |
| LBRX | Chief Executive Officer | — | $45.30 | — | $0 | 1 | 2025-09-12 |
| LYEL | Chief General Counsel | — | $17.25 | — | $0 | 1 | 2022-03-18 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | EVP, General Counsel & Sec. | 19,250 | $0.18 | $3.4K | $0 | 2 | 2019-02-27 |
| ATRA | Former EVP, GC & Sec. | 2,920 | $8.10 | $23.7K | -$656.3K | 8 | 2018-02-12 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | SVP, Gen. Counsel & Secretary | 2,264 | — | — | -$2.29M | 19 | 2015-02-05 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-05 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-05-01 | AVLN | Grant (A) | — | $0 | EDGAR |
| 2026-02-02 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-09-12 | LBRX | Mixed | — | $0 | EDGAR |
| 2025-06-12 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-11-19 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-18 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2019-02-27 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +19,250 | $0 | EDGAR |
| 2018-03-02 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-02-12 | ATRA | Sell (S) | −12,214 | -$464.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.